Patents Assigned to Genentech
  • TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180086757
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • Methods of treating and preventing cancer drug resistance
    Patent number: 9925240
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 27, 2018
    Assignee: GENENTECH, INC.
    Inventors: Robert L. Yauch, Xiaofen Ye, Avi Ashkenazi
  • Gram-positive bacteria specific binding compounds
    Patent number: 9927428
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 27, 2018
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Anti-GPC3 antibodies and immunoconjugates
    Patent number: 9926377
    Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 27, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Youjun Chen
  • ANTI-IL-17A AND IL-17F CROSS REACTIVE ANTIBODY VARIANTS AND COMPOSITIONS COMPRISING AND METHODS OF MAKING AND USING SAME
    Publication number: 20180079807
    Abstract: The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.
    Type: Application
    Filed: April 28, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: GALAHAD DEPERALTA, AARON WECKSLER, MELISSA ALVAREZ
  • METHODS AND COMPOSITIONS FOR PREVENTING NORLEUCINE MISINCORPORATION INTO PROTEINS
    Publication number: 20180080056
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Application
    Filed: November 17, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20180080080
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: MICHAEL TOWNSEND, ALVERNIA FRANCESCA SETIADI, TRACY STATON
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20180079826
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Anti-PD-L1 antibodies, compositions and articles of manufacture
    Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Methods and compositions comprising purified recombinant polypeptides
    Patent number: 9920120
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180072683
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
  • HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
    Publication number: 20180071286
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 15, 2018
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Notch pathway inhibition
    Patent number: 9914774
    Abstract: The invention provides Notch pathway inhibition with reduced toxicity.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 13, 2018
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Fred de Sauvage, Christian Siebel, Brian Biehs, Hua Tian, Ophir Klein
  • TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20180065983
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 8, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • Anti-hemagglutinin antibodies and methods of use
    Patent number: 9908931
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 6, 2018
    Assignee: GENENTECH, INC.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhaoyu Jin, Zhonghua Lin, Patrick Lupardus, Gerald r. Nakamura, Hyunjoo Park, Lee Swem
  • Mutant smoothened and methods of using the same
    Patent number: 9910050
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 6, 2018
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Frederic J. de Sauvage, Gerrit J. P. Dijkgraaf, Thomas Januario, Robert L. Yauch
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20180057500
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Applicant: Genentech, Inc.
    Inventors: Roland J BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • ANTI-TRANSFERRIN RECEPTOR / ANTI-BACE1 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
    Publication number: 20180057604
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 1, 2018
    Applicants: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan WU, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE
    Publication number: 20180057598
    Abstract: Provided herein are tetravalent antigen binding complexes having agonist activity for a cell surface receptor. In some embodiments, the complexes comprise binding specificities for multiple epitopes of the same cell surface receptor. Further provided herein are nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production related thereto.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 1, 2018
    Applicant: Genentech, Inc.
    Inventors: Greg LAZAR, Yanli YANG, Erin H. CHRISTENSEN, Julie HANG, Jeong KIM, Seth HARRIS
  • ANTI-NOTCH2 NRR ANTIBODIES
    Publication number: 20180057589
    Abstract: The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.
    Type: Application
    Filed: July 21, 2017
    Publication date: March 1, 2018
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu